To overcome this, an alternative virus-based therapeutic strategy was developed: the adenoviral vector expressing GFP-TRAIL fusion protein showed significant antitumor effects against intracranial xenografts of high-grade malignant meningioma and glioma [29]. The gene discussed is TNFSF10; the disease is central nervous system cancer.